SOPHIA ANTIPOLIS, France – September 03, 2024 │ The last quarterly report for the 2024 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Monkeypox virus, a new threat? Mpox, also known as monkeypox, is a viral disease caused by the[…]
SOPHIA ANTIPOLIS, France – January 16, 2024 │ The last quarterly report for the 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. As we leave behind another year, we look back on the mRNA therapeutic patenting activity! Q4 2023[…]
SOPHIA ANTIPOLIS, France – November 27, 2023 │Acuitas Therapeutics filed a complaint on November 13, 2023, against CureVac SE seeking a declaratory judgment of inventorship regarding the US patents 11,241,493; 11,471,525; 11,576,966; and 11,596,686 (collectively referred to as Patent Family ‘493). According to the complaint (Case 3:23-cv-00764), the patents in question were wrongfully assigned to[…]
SOPHIA ANTIPOLIS, France – November 06, 2023 │ReNAgadeTherapeutics, a company founded in 2021 and based in Cambridge, presented preclinical data demonstrating a new and proprietary method of delivering mRNA to extra-hepatic tissues in non-human primate using lipid nanoparticles (LNPs) at the 11th International mRNA Health Conference, taking place from October 31 to November 2, 2023[…]